The US Food and Drug Administration (FDA) has approved avatrombopag (Doptelet, AkaRx Inc) to increase platelet counts in adults with thrombocytopenia and chronic liver disease who are to undergo a ...
The approval of Doptelet was based on results from the ADAPT-1 (N=231) and ADAPT-2 trials (N=204), 2 identically-designed multicenter, randomized, double-blind, placebo-controlled studies. The Food ...
WASHINGTON -- The FDA approved another thrombopoietin receptor agonist on Monday, for an indication not covered by other drugs intended to raise platelet counts. The new agent is avatrombopag ...
Patients undergoing transcatheter aortic valve replacement (TAVR) have decreases in platelet counts that are typically transient, lasting just a few days. But in those with preexisting ...
What Is Doptelet, and Why Does It Matter? Doptelet (avatrombopag) is a prescription medicine that helps the body make more platelets (cells that help stop bleeding). First approved in 2018 for adults, ...
Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...
Research has proven frozen blood platelets are safe and effective for use in critically injured patients—a breakthrough dramatically extending their shelf life for transfusions from one week to two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback